Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin‐17 levels in bleomycin‐induced dermal fibrosis
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.14114
Abstract: Although the pathogenesis of systemic sclerosis is not exactly known, it is thought that immune activation has prominent roles in pathogenesis. Secukinumab is a monoclonal antibody against interleukin (IL)‐17A. Metformin, a widely used antidiabetic medication,… read more here.
Keywords: dermal fibrosis; fibrosis; induced dermal; tissue ... See more keywords